<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug-induced thrombotic microangiopathy (DITMA)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug-induced thrombotic microangiopathy (DITMA)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Drug-induced thrombotic microangiopathy (DITMA)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James N George, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam Cuker, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Crowther, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H11462639"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thrombotic microangiopathies (TMAs) are potentially life-threatening conditions caused by small-vessel platelet thrombi. Characteristic clinical features are microangiopathic hemolytic anemia (MAHA) and thrombocytopenia. Acute kidney injury (AKI), neurologic abnormalities, and/or cardiac ischemia may be seen. (See <a class="local">'Clinical manifestations'</a> below.)</p><p>Drug-induced TMA (DITMA) is challenging to diagnose because laboratory tests to identify a drug etiology may not be available. Some of the implicated substances may not be acknowledged by the patient, and <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> exposure may be from a beverage such as tonic water. </p><p>The principal treatment of DITMA is withdrawing the suspected drug and providing supportive care. Management may be challenging because it may be difficult to distinguish DITMA from other primary TMAs. (See <a class="local">'Management'</a> below and <a class="local">'Differential diagnosis'</a> below.)</p><p>Here we discuss our approach to the evaluation and management of a patient with a suspected DITMA.</p><p>Separate topic reviews discuss:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach to evaluating TMAs</strong> – (See  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombotic thrombocytopenic purpura (TTP) diagnosis</strong> – (See  <a class="medical medical_review" href="/d/html/1338.html" rel="external">"Diagnosis of immune TTP"</a> and  <a class="medical medical_review" href="/d/html/101504.html" rel="external">"Hereditary thrombotic thrombocytopenic purpura (hTTP)", section on 'Diagnostic evaluation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>TTP treatment</strong> – (See  <a class="medical medical_review" href="/d/html/1344.html" rel="external">"Immune TTP: Initial treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complement-mediated TMAs</strong> – (See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a> and  <a class="medical medical_review" href="/d/html/114693.html" rel="external">"Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS"</a>.)</p><p></p><p class="headingAnchor" id="H10429223"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Terminology for the TMA syndromes is evolving as disease understanding increases and diagnostic testing allows identification of specific causes. (See  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)", section on 'Terminology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>DITMA versus DI-TTP</strong> – Drug-induced TMA (DITMA) is a TMA <strong>without</strong> ADAMTS13 deficiency, caused by exposure to a drug or other substance such as a food or beverage. </p><p></p><p class="bulletIndent1">The term drug-induced thrombotic thrombocytopenic purpura (DI-TTP) is used when the diagnosis of TTP is supported by severe ADAMTS13 deficiency (activity ≤10 percent) and the etiology of TTP can be confidently attributed to a drug such as an immune checkpoint inhibitor or other drug. DI-TTP is discussed separately. (See  <a class="medical medical_review" href="/d/html/1338.html" rel="external">"Diagnosis of immune TTP", section on 'Evaluation and diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune versus non-immune DITMA</strong> – We divide DITMA into immune-mediated syndromes, which can occur after exposure to any amount of the drug and are due to an idiosyncratic, antibody-dependent mechanism, and non-immune syndromes, which do not involve drug-dependent antibodies; the non-immune syndromes are much more common and generally are dose related [<a href="#rid1">1-3</a>].</p><p></p><p class="bulletIndent1">Implications of this distinction include differences in presentation, management, and prognosis; however, for many reports, the mechanism (immune versus non-immune) is uncertain. (See <a class="local">'Clinical manifestations'</a> below and <a class="local">'Management'</a> below and <a class="local">'Prognosis/expected recovery'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> is the only drug for which immune- and non-immune-mediated mechanisms have been documented; however, as with other drugs, most case reports for gemcitabine lack evidence sufficient for a probable or definite causal association. (See <a class="local">'Gemcitabine'</a> below and <a class="local">'Cancer therapies'</a> below.)</p><p></p><p class="headingAnchor" id="H10429235"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H3859294987"><span class="h2">Overview of pathophysiology</span><span class="headingEndMark"> — </span>Immune DITMA results from exposure to a drug (medication, other substance) that interacts with a naturally occurring antibody that can then bind to a cell surface epitope [<a href="#rid4">4</a>]. Non-immune DITMA is caused by direct tissue injury. Unlike some secondary TMAs, DITMA does not appear to be associated with an increased prevalence of pathogenic variants in complement genes. </p><p>As with other TMAs, thrombocytopenia results from platelet consumption in microthrombi, and microangiopathic hemolytic anemia (MAHA) occurs as red blood cells (RBCs) become fragmented by the turbulent circulation as they pass across these thrombi. Organ ischemia and infarction may also occur as a result of small-vessel thrombosis. The kidney appears to be especially susceptible in DITMA syndromes.</p><p>Additional information about the pathogenesis of TMAs is presented separately. (See  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)"</a>.)</p><p class="headingAnchor" id="H21437823"><span class="h2">Immune-mediated mechanisms</span><span class="headingEndMark"> — </span>Immune-mediated DITMA is caused by drug-dependent antibodies, as illustrated in the figure  (<a class="graphic graphic_figure graphicRef130247" href="/d/graphic/130247.html" rel="external">figure 1</a>). </p><p>Patients who are susceptible to immune DITMA have pre-existing antibodies that react very weakly with multiple cells including platelets, neutrophils, and endothelial cells in the absence of the drug [<a href="#rid4">4,5</a>]. Strong binding of these antibodies only occurs in the presence of the drug (or drug metabolite). These antibodies are described as drug-dependent antibodies.</p><p>Characteristics of the drug-dependent antibodies:</p><p class="bulletIndent1"><span class="glyph">●</span>May be highly specific for the structure of the implicated drug [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Require the drug (or a drug metabolite) to be present to cause cellular damage. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once the drug is cleared from the circulation (hours to days for most drugs), no new organ injury occurs. However, tissue damage (especially kidney injury) may recover slowly and/or incompletely, and MAHA and thrombocytopenia may be slow to resolve. (See <a class="local">'Prognosis/expected recovery'</a> below.)</p><p></p><p class="headingAnchor" id="H21437829"><span class="h2">Non-immune mechanism</span><span class="headingEndMark"> — </span>Non-immune DITMA may develop by multiple mechanisms. It may occur with high cumulative doses of a drug over a long time period, or it may occur with a single exposure. </p><p>Non-immune DITMA generally results from direct tissue injury from the implicated agent. </p><p class="headingAnchor" id="H82111"><span class="h1">DRUGS ASSOCIATED WITH DITMA</span></p><p class="headingAnchor" id="H83404"><span class="h2">Overview of drugs and criteria</span><span class="headingEndMark"> — </span>A number of drugs have been implicated in causing DITMA (sometimes reported as drug-induced thrombotic thrombocytopenic purpura [DI-TTP] or drug-induced hemolytic uremic syndrome [HUS]). We reserve DI-TTP for drug-induced TMA with severe ADAMTS13 deficiency. (See <a class="local">'Terminology'</a> above.)</p><p>The most common drugs with the strongest evidence for a causal association with DITMA are listed in the table  (<a class="graphic graphic_table graphicRef101685" href="/d/graphic/101685.html" rel="external">table 1</a>); these are drugs for which at least one report has documented definite evidence for a causal association with TMA, or two reports documenting probable evidence. Selected drugs are discussed below. (See <a class="local">'Drugs (immune mechanism)'</a> below and <a class="local">'Drugs (non-immune mechanism)'</a> below.)</p><p>Many additional drugs have been reported to cause DITMA without data supporting a definite or probable association. The evidence for the role of these drugs was evaluated in a systematic review of published reports based on stringent criteria for the level of supporting evidence [<a href="#rid1">1-3,6,7</a>].</p><p>Evidence is lacking for a role of the thienopyridine antiplatelet agents that block the platelet P2Y<sub>12 </sub>receptor (<a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="9996" href="/d/drug information/9996.html" rel="external">ticlopidine</a>), despite multiple published reports [<a href="#rid8">8,9</a>]. Patients receiving these agents were also receiving multiple other medications, or their TMA recurred without re-exposure to the drug. </p><p>For drugs that have not been reported but that have a presentation consistent with an immune-mediated mechanism (abrupt onset, history of previous drug exposure associated with systemic symptoms only appreciated in retrospect), testing for drug-dependent antibodies is important for establishing the diagnosis, advising the patient whether the drug should be avoided, and reporting of new DITMA associations. (See <a class="local">'Laboratory testing'</a> below.) </p><p class="headingAnchor" id="H3955639"><span class="h2">Drugs (immune mechanism)</span></p><p class="headingAnchor" id="H590279569"><span class="h3">Quinine</span><span class="headingEndMark"> — </span>Until 2010, <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> was the most common cause of immune-mediated DITMA [<a href="#rid10">10</a>]. Quinine-induced DITMA has subsequently become rare since the US Food and Drug Administration (FDA) began requiring a prescription for quinine tablets and the approval of quinine was limited to treatment of malaria. DITMA can be caused by quinine in beverages such as tonic water, but this is rare [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H83307"><span class="h3">Antimicrobials</span><span class="headingEndMark"> — </span>The antibiotic with the best evidence is <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>. A number of other antibiotics have evidence for causing immune-mediated DITMA in single case reports, including [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Sulfisoxazole</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a></p><p class="bulletIndent1"><span class="glyph">●</span>Penicillin</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">Metronidazole</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">Mefloquine</a> (antimalarial)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">Famciclovir</a> (antiviral)</p><p></p><p><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> has been associated with DITMA according to the prescribing information [<a href="#rid11">11</a>]. Case reports have been published associating DITMA or DI-TTP with rifampin, although causation has not been well-established [<a href="#rid12">12,13</a>].</p><p class="headingAnchor" id="H83335"><span class="h3">Gemcitabine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> has been reported to cause non-immune DITMA (see <a class="local">'Cancer therapies'</a> below); there is also a report of immune-mediated DITMA from gemcitabine [<a href="#rid14">14</a>]. Immune-mediated DITMA from gemcitabine is less common than the non-immune mechanism.</p><p class="headingAnchor" id="H83397"><span class="h3">Oxaliplatin</span><span class="headingEndMark"> — </span>One report has described definite evidence for DITMA caused by <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> with the clinical features of an immune-mediated etiology (although the authors of this report attributed the TMA to <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>) [<a href="#rid15">15</a>]. The laboratory of the Versiti Blood Center of Wisconsin (Milwaukee) has also identified oxaliplatin-dependent, platelet-reactive antibodies in a patient with clinical features of TMA [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H83372"><span class="h3">Quetiapine</span><span class="headingEndMark"> — </span>The antipsychotic agent <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> has been associated with DITMA that recurred with repeated exposures, suggestive of an immune mechanism [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H83424"><span class="h3">Immunomodulatory agents</span><span class="headingEndMark"> — </span>The anti-T cell monoclonal antibody muromonab-CD3 (OKT3) and the anti-tumor necrosis factor (TNF) monoclonal antibody <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> have been reported to cause immune-mediated DITMA [<a href="#rid17">17-19</a>]. Calcineurin inhibitors appear to cause non-immune DITMA. (See <a class="local">'Immunosuppressive agents'</a> below.)</p><p class="headingAnchor" id="H3955646"><span class="h2">Drugs (non-immune mechanism)</span><span class="headingEndMark"> — </span>The three major categories of drugs associated with non-immune DITMA are cancer therapies, immunosuppressive agents, and drugs of abuse. The hemophilia A therapy <a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">emicizumab</a> has also been reported to cause DITMA.</p><p class="headingAnchor" id="H174813"><span class="h3">Cancer therapies</span><span class="headingEndMark"> — </span>DITMA from chemotherapeutic agents often results from dose-dependent toxicity, which may be either from a cumulative dose over weeks to months or from an unusually high individual dose  (<a class="graphic graphic_table graphicRef101685" href="/d/graphic/101685.html" rel="external">table 1</a>). </p><p>When DITMA occurs from a cumulative dose, the clinical course is characterized by gradual development of kidney injury (acute kidney injury or chronic kidney disease), sometimes occurring even after the chemotherapy has been stopped. When it occurs because of an unusually high dose, the onset is sudden, similar to immune DITMA. (See <a class="local">'Clinical features of immune DITMA'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gemcitabine</strong> – Hundreds of cases of gemcitabine-induced DITMA have been reported [<a href="#rid1">1,6,20</a>]. However, only 17 of these reports described definite or probable evidence for a causal association with TMA. </p><p></p><p class="bulletIndent1">The mechanism appears to be dose related in most patients. One series of 264 patients who received <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> reported development of a TMA in three (1 percent) [<a href="#rid21">21</a>]. One patient had a relatively large cumulative dose; the other two did not. There is also a report of immune-mediated DITMA from gemcitabine [<a href="#rid14">14</a>]. (See <a class="local">'Drugs (immune mechanism)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitomycin</strong> – <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">Mitomycin</a> has been associated with DITMA in case reports and pharmacovigilance studies [<a href="#rid1">1,20</a>]. Only six reports have presented definite or probable evidence for mitomycin as the cause because mitomycin is almost always given in combination with other drugs [<a href="#rid22">22-30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pentostatin</strong> – Two reports have described definite evidence supporting a causal association of <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> with DITMA [<a href="#rid31">31,32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vincristine</strong> – One report has described definite evidence supporting a causal association of <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> with DITMA [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proteasome inhibitors</strong> – Many cases of DITMA have been described with proteasome inhibitors (<a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a>, and <a class="drug drug_general" data-topicid="105607" href="/d/drug information/105607.html" rel="external">ixazomib</a>) [<a href="#rid6">6,20,34-40</a>]. Some had recurrence of TMA following re-exposure to the drug. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular endothelial growth factor (VEGF) inhibitors and tyrosine kinase inhibitors </strong>– VEGF inhibition in glomerular endothelial cells impairs the unique permeability characteristics of these cells and promotes microvascular injury [<a href="#rid41">41</a>]. </p><p></p><p class="bulletIndent1">Implicated agents include the antiangiogenic monoclonal antibody <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, and the small molecule tyrosine kinase inhibitors <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="87456" href="/d/drug information/87456.html" rel="external">ponatinib</a>, and <a class="drug drug_general" data-topicid="8852" href="/d/drug information/8852.html" rel="external">dasatinib</a> [<a href="#rid3">3,41-47</a>]. (See  <a class="medical medical_review" href="/d/html/2794.html" rel="external">"Overview of angiogenesis inhibitors"</a> and  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematopoietic cell transplantation</strong> – TMA has been described after hematopoietic stem cell transplant (allogeneic or autologous); the incidence varies from 1 to 20 percent [<a href="#rid48">48,49</a>]. (See  <a class="medical medical_review" href="/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation", section on 'Thrombotic microangiopathy'</a> and  <a class="medical medical_review" href="/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Thrombotic microangiopathy'</a>.)</p><p></p><p class="bulletIndent1">DITMA may be the etiology of TMA in these patients because they have typically received cytotoxic chemotherapy and/or immunosuppressive therapy. </p><p></p><p class="headingAnchor" id="H10432322"><span class="h3">Immunosuppressive agents</span><span class="headingEndMark"> — </span>Calcineurin inhibitors such as <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> A (CSA) and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> cause dose-dependent endothelial dysfunction and increased platelet aggregation, possibly by inhibiting prostacyclins [<a href="#rid50">50</a>]. Organ involvement typically is restricted to the kidneys [<a href="#rid51">51</a>].</p><p><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a>, which inhibits the mechanistic target of rapamycin (mTOR), can also cause DITMA, alone or in combination with CSA [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors", section on 'Hemolytic uremic syndrome/thrombotic microangiopathy'</a>.)</p><p>The tumor necrosis factor (TNF) inhibitor <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> has been implicated. TNF inhibitors have a number of toxicities that could be responsible. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p>DITMA from the monoclonal antibody OKT3 and from the immunomodulatory agent <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> appears to be immune mediated. (See <a class="local">'Immunomodulatory agents'</a> above.)</p><p>A causative role for interferon was suggested in a series of eight patients with multiple sclerosis who developed TMA during treatment with interferon beta, as there did not appear to be other causes [<a href="#rid53">53,54</a>]. DITMA occurred exclusively in those who received an interferon dose above 50 mcg per week, and the effect appeared to be dose dependent. Subsequent studies in transgenic mice engineered to produce type 1 interferon in the brain demonstrated that interferon caused dose-dependent TMA [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H1323021"><span class="h3">Drugs of abuse</span><span class="headingEndMark"> — </span>DITMA has been reported with certain drugs of abuse, including [<a href="#rid55">55-58</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous use of the extended-release opioid <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a> </p><p class="bulletIndent1"><span class="glyph">●</span>Ecstasy (MDMA, also known as Molly)</p><p class="bulletIndent1"><span class="glyph">●</span>Cocaine</p><p></p><p>A unique mechanism is the increased blood viscosity caused by Opana ER and <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> [<a href="#rid58">58-61</a>]. Opana ER and oxycodone (OxyContin) contain a high molecular weight inert ingredient, polyethylene oxide (PEO; molecular weight, approximately 7 million Daltons), that mediates DITMA.</p><p>PEO was added to <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a> tablets in 2012 to resist crushing and solubilization and to decrease the risk of intravenous abuse. However, PEO causes increased blood viscosity, hemolysis, and hemoglobinuric kidney injury [<a href="#rid58">58</a>]. Subsequently, DITMA was reported with intravenous use of <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> intended for oral administration that had added PEO [<a href="#rid59">59-61</a>]. </p><p class="headingAnchor" id="H2696328421"><span class="h3">Emicizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">Emicizumab</a> is used for prophylaxis against bleeding in individuals with hemophilia A (factor VIII deficiency). (See  <a class="medical medical_review" href="/d/html/107911.html" rel="external">"Hemophilia A and B: Routine management including prophylaxis", section on 'Emicizumab for hemophilia A'</a>.)</p><p>Early experience identified TMA in three individuals with hemophilia A who had factor VIII inhibitors and were treated with <a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">emicizumab</a> along with high doses of <a class="drug drug_general" data-topicid="8434" href="/d/drug information/8434.html" rel="external">activated prothrombin complex concentrate</a> (aPCC; factor eight inhibitor bypassing agent [FEIBA]) [<a href="#rid62">62</a>]. Discontinuation of aPCC led to resolution of the TMA in all three. This led to a Boxed Warning in the product information and advice to avoid combining high doses of emicizumab with an aPCC. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)", section on 'Regulators of clotting or fibrinolysis'</a>.) </p><p class="headingAnchor" id="H686024097"><span class="h2">Gene therapy (mechanism unclear)</span><span class="headingEndMark"> — </span>A few case reports have described DITMA in patients treated with certain gene therapy constructs.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>SMA</strong> – The gene therapy construct <a class="drug drug_general" data-topicid="121399" href="/d/drug information/121399.html" rel="external">onasemnogene abeparvovec</a> provides a normal copy of the <em>SMN1</em> gene to patients with spinal muscular atrophy (SMA). The construct uses an adeno-associated virus (AAV) vector with tropism to the liver and other tissues [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/6146.html" rel="external">"Spinal muscular atrophy", section on 'Onasemnogene abeparvovec'</a>.)</p><p></p><p class="bulletIndent1">Several cases of TMA have been reported, including TMA with fatal complications, in infants and young children treated with <a class="drug drug_general" data-topicid="121399" href="/d/drug information/121399.html" rel="external">onasemnogene abeparvovec</a> [<a href="#rid64">64,65</a>]. The time course was rapid (within one week to 10 days). The clinical presentations included severe thrombocytopenia, microangiopathic hemolysis with schistocytes on the blood film, transaminase elevations, and acute kidney injury (AKI) progressing to kidney failure. The role of complement abnormalities is unclear; one individual had a variant of uncertain significance (VUS) in the gene for complement factor I [<a href="#rid64">64</a>]. Some had concomitant infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other conditions</strong> – TMA may have occurred with other gene therapy constructs, but details are limited. Thrombocytopenia with complement activation was seen in some individuals treated with an investigational gene therapy construct for degenerative muscular dystrophy (DMD), and one case of TMA was seen following treatment with an investigational gene therapy construct for Danon disease, although specific findings have not been published [<a href="#rid66">66,67</a>].</p><p></p><p>Possible mechanisms of TMA may include the gene therapy construct itself; inflammation induced by the gene therapy, underlying condition, or other interventions; complement dysregulation; other genetic variants; or other aspects of the patient's underlying disorder. Further research is needed. (See  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)", section on 'Complement-mediated TMA pathogenesis'</a>.)</p><p class="headingAnchor" id="H10429242"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>DITMA is uncommon. In a review of 487 patients in the Oklahoma TTP Registry that included all patients with microangiopathic hemolytic anemia (MAHA) and thrombocytopenia referred for plasma exchange, DITMA with definite or probable evidence supporting a causal association with the suspected drug accounted for 23 cases (5 percent) [<a href="#rid2">2</a>].</p><p>DITMA is mostly seen in adults although, rarely, children may be affected. This distribution probably reflects the greater likelihood that adults are exposed to implicated drugs.</p><p class="headingAnchor" id="H10429249"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Characteristic clinical features of DITMA are microangiopathic hemolytic anemia (MAHA) and thrombocytopenia; acute kidney injury (AKI), neurologic abnormalities, and/or cardiac ischemia may be seen [<a href="#rid68">68</a>]. </p><p>Disease severity varies widely. All patients have MAHA and thrombocytopenia, and most have kidney injury. </p><p class="headingAnchor" id="H10429427"><span class="h2">Clinical features of immune DITMA</span><span class="headingEndMark"> — </span>Patients with immune-mediated DITMA may have a history of daily exposure to the implicated drug for less than two to three weeks; a longer duration of daily drug exposure makes immune-mediated DITMA much less likely. There may have been intermittent exposure for years without any apparent illness or a history of nonspecific illness with previous exposures that was not attributed to the drug at the time they occurred [<a href="#rid5">5,10</a>].</p><p>The classic clinical features of immune-mediated DITMA are illustrated by the experience with quinine-induced DITMA [<a href="#rid5">5,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The onset is sudden (within hours after <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> exposure).</p><p class="bulletIndent1"><span class="glyph">●</span>Severe systemic symptoms include chills, fever, abdominal pain, diarrhea, and/or nausea/vomiting.</p><p class="bulletIndent1"><span class="glyph">●</span>Patients can often recall the exact time and place when these symptoms began. </p><p class="bulletIndent1"><span class="glyph">●</span>Anuric AKI is often misinterpreted as a manifestation of dehydration. Often, the onset of anuria is abrupt (within hours). </p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic findings may range from mild confusion to coma. </p><p class="bulletIndent1"><span class="glyph">●</span>Acute gastrointestinal symptoms may manifest as nausea, vomiting, diarrhea, or abdominal pain.</p><p></p><p>Patients with quinine-induced DITMA may also have additional organ involvement [<a href="#rid69">69</a>]. There may be disseminated intravascular coagulation (DIC) mimicking sepsis [<a href="#rid70">70-72</a>]. Rhabdomyolysis or acute liver injury may occur [<a href="#rid70">70,73</a>]. Many organ systems may be involved (fever, chills, hypotension, DIC, abnormal liver function, rhabdomyolysis, and cardiac ischemia) [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H84233"><span class="h2">Clinical features of non-immune DITMA</span><span class="headingEndMark"> — </span>DITMA caused by a dose-dependent mechanism may develop gradually over weeks to months with weakness, fatigue, symptoms of hypertension such as headache, and/or kidney failure [<a href="#rid68">68</a>]. </p><p>For chemotherapeutic agents, the findings may occur after several cycles of chemotherapy; some patients have a systemic malignancy, whereas others have a small tumor burden or no sign of disease [<a href="#rid75">75-78</a>]. There may be weeks to months of progressive kidney injury that may be attributed to other comorbidities. Neurologic findings may range from mild confusion to coma.</p><p>DITMA associated with cocaine or intravenous use of extended-release <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a> (Opana ER) may present with sudden-onset MAHA, thrombocytopenia, and AKI [<a href="#rid55">55,58-61,79</a>].</p><p>Other laboratory findings are discussed below. (See <a class="local">'Laboratory testing'</a> below.)</p><p class="headingAnchor" id="H10429256"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H2466304545"><span class="h2">When to suspect DITMA</span><span class="headingEndMark"> — </span>DITMA may be suspected in any individual who presents with an unexplained decrease in platelet count and schistocytes on the blood smear, typically with worsening kidney function. Most individuals have thrombocytopenia and hemolytic anemia and are receiving one of the implicated drugs. </p><p>DITMA may be considered even in the absence of these findings, such as when there is compensated hemolysis or an early change in platelet count or creatinine that is not severe enough to trigger a laboratory flag.</p><p class="headingAnchor" id="H2302673"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>The history should focus on drugs that have been reported with definite or probable evidence for a causal association  (<a class="graphic graphic_table graphicRef101685" href="/d/graphic/101685.html" rel="external">table 1</a>). </p><p>Especially important are over-the-counter remedies and illicit drug use, which are not considered medications and are generally not reported by patients unless specifically queried. </p><p>Implicated recreational drugs include ecstasy (MDMA, also known as Molly), cocaine, and opioid medications used by an inappropriate route (eg, intravenous administration of extended-release <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a> [Opana ER] or <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> [OxyContin], which are intended to be taken orally).</p><p>The remainder of the history and physical examination is similar to other suspected primary TMAs. A high level of suspicion for other potential systemic causes of microangiopathic hemolytic anemia (MAHA) and thrombocytopenia and other primary TMAs should be maintained. (See  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)", section on 'Initial evaluation (all patients)'</a>.)</p><p class="headingAnchor" id="H2303161"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Laboratory testing includes the testing done for all patients with a suspected primary TMA. </p><p class="headingAnchor" id="H1980722351"><span class="h3">Testing for all patients</span><span class="headingEndMark"> — </span>Some tests are used to find alternative causes of MAHA and thrombocytopenia. The following is appropriate, if not done already:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count (CBC) with platelet count and examination of a peripheral blood smear</p><p class="bulletIndent1"><span class="glyph">●</span>Serum metabolic profile and creatinine</p><p class="bulletIndent1"><span class="glyph">●</span>Lactate dehydrogenase (LDH)</p><p class="bulletIndent1"><span class="glyph">●</span>Coombs testing (also called direct antiglobulin testing [DAT])</p><p class="bulletIndent1"><span class="glyph">●</span>Coagulation testing with prothrombin time (PT) and activated partial thromboplastin time (aPTT)</p><p class="bulletIndent1"><span class="glyph">●</span>ADAMTS13 activity level</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis  (<a class="graphic graphic_table graphicRef56160" href="/d/graphic/56160.html" rel="external">table 2</a>) (see  <a class="medical medical_review" href="/d/html/7196.html" rel="external">"Urinalysis in the diagnosis of kidney disease"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Stool testing for Shiga toxin if diarrhea is present</p><p></p><p>DITMA is characterized by:</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia with high LDH and schistocytes  (<a class="graphic graphic_picture graphicRef70851" href="/d/graphic/70851.html" rel="external">picture 1</a>) on the blood smear</p><p class="bulletIndent1"><span class="glyph">●</span>Negative DAT</p><p class="bulletIndent1"><span class="glyph">●</span>Normal PT and aPTT</p><p class="bulletIndent1"><span class="glyph">●</span>ADAMTS13 activity &gt;20 percent</p><p></p><p>It is also possible to have a platelet count within the normal range if the count represents a significant decrease from the patient's baseline (eg, decline from 350,000/microL to 150,000/microL). </p><p>Kidney insufficiency with increased serum creatinine, proteinuria, and a bland urine sediment is common.</p><p>Evidence of severe complement dysregulation is also absent, but nonspecific findings such as low C3 or C4 may be seen. </p><p>Stool studies in DITMA are negative for Shiga toxin-producing <em>Escherichia coli</em> or other diarrheal organisms.</p><p>Acute kidney injury (AKI) that is progressive or requires dialysis may indicate complement-mediated TMA, which requires anticomplement therapy. Evaluation and management of complement-mediated TMA are presented separately. (See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>.)</p><p>ADAMTS13 activity is normal or only mildly decreased in DITMA. A finding of severe ADAMTS13 deficiency (activity ≤10 percent) at any time during the evaluation for DITMA is strong evidence for the diagnosis of thrombotic thrombocytopenic purpura (TTP), which requires urgent therapeutic plasma exchange (TPE) and other therapies. Drug-induced TTP (DI-TTP) with severe ADAMTS13 deficiency is considered a type of TTP rather than DITMA. (See <a class="local">'Differential diagnosis'</a> below.) </p><p class="headingAnchor" id="H913041295"><span class="h3">Additional testing for selected individuals</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney biopsy</strong> – Kidney biopsy is not required in the evaluation of DITMA, nor is it helpful in confirming the diagnosis or eliminating other causes of TMA. However, a kidney biopsy may appropriately be performed if the etiology of the AKI is not apparent (eg, possible acute tubular necrosis [ATN] in the setting of hypotension). </p><p></p><p class="bulletIndent1">Kidney biopsy may be especially useful in individuals with heavy (nephrotic range) proteinuria, who may have nephrotic syndrome due to another cause (eg, paraneoplastic membranous nephropathy or minimal change disease in a patient with cancer). </p><p></p><p class="bulletIndent1">If kidney biopsy (or biopsy of another affected organ) is performed, it is likely to show typical findings of TMA such as platelet-rich thrombi in small arterioles and capillaries, which are described in detail separately. (See  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)", section on 'Histopathology of TMA'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-dependent antibodies</strong> – Patients with suspected immune-mediated DITMA based on the history and clinical presentation may benefit from testing for drug-dependent antibodies, especially in cases where it is necessary to determine which of several potential drugs is responsible or if knowledge of the need to avoid a specific drug or substance for life would be valuable to the patient. This testing is available at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.versiti.org%2Fmedical-professionals%2Fproducts-services%2Fdiagnostic-labs&amp;token=uvPzThd2jHazSsAmPYthZlx%2FHt%2BEpbaUhZJfq0W2iN553JzV%2BUjOHQIe3kPFQ0Hvea5zlf6%2Bn5vgjojHfRQZ%2FhBJmG3G0mWspz91ZM4JpYA%3D&amp;TOPIC_ID=98720" target="_blank">Versiti Blood Center of Wisconsin</a> [<a href="#rid80">80</a>]. </p><p></p><p class="bulletIndent1">The finding of drug-dependent antibodies necessitates complete avoidance of the implicated drug or substance for life; however, the converse is not true (lack of identification of drug-dependent antibodies cannot be used as evidence that a drug is safe), and decisions regarding future drug avoidance must be made on a case-by-case basis. (See <a class="local">'Future drug avoidance'</a> below.)</p><p></p><p class="bulletIndent1">Identification of drug-dependent antibodies associated with a drug not previously reported to cause DITMA is valuable both for management of the individual patient as well as making other clinicians aware of the potential association (eg, by description in a publication or reporting to the US Food and Drug Administration [FDA] <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fmedwatch%2Findex.cfm%3Faction%3Dreporting.home&amp;token=HKkZOQQqv3WSNQrw2%2FpEDshXhD7yBZkvpT56IPC73znhZVIJlPjGA77E9KAaYQtOnXEZDozS7NfJcitPwLls7GjOhXqKOknoxGP8iVepfyI%3D&amp;TOPIC_ID=98720" target="_blank">MedWatch</a> program in the United States) [<a href="#rid81">81</a>].</p><p></p><p class="headingAnchor" id="H10429468"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of DITMA is made clinically, based on MAHA and thrombocytopenia with the appropriate history of exposure to a drug previously documented to be associated with TMA  (<a class="graphic graphic_table graphicRef101685" href="/d/graphic/101685.html" rel="external">table 1</a>). There is no specific diagnostic test; however, drug-dependent antibodies may be demonstrated.</p><p>Our confidence in the diagnosis is increased when the drug has previously been reported to be associated with DITMA based on definite or probable evidence for a causal relationship (presence of drug-dependent antibodies, no other drug exposures, appropriate temporal relationship) [<a href="#rid1">1,2</a>]. </p><p>If severe ADAMTS13 deficiency (activity ≤10) or ADAMTS13 activity of 11 to 20 percent is documented, the diagnosis is probably TTP or DI-TTP. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H10429475"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>There is clinical overlap between DITMA and other primary TMAs, and clinical features that clearly distinguish DITMA from other primary TMAs are lacking.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other primary</strong> <strong>TMAs</strong> – Other primary TMAs include thrombotic thrombocytopenic purpura (TTP), complement-mediated TMA, Shiga toxin-mediated hemolytic uremic syndrome (ST-HUS), and TMA due to inherited defects in genes involved in regulating hemostasis or cobalamin metabolism. Like DITMA, these conditions can present with an acute, life-threatening illness, microangiopathic/fragmentation hemolysis, thrombocytopenia, and organ damage, especially kidney failure. Unlike DITMA, these other TMAs often reveal a specific diagnosis from appropriate laboratory testing, such as severe ADAMTS13 deficiency or a Shiga toxin-producing diarrheal organism. Other distinguishing factors are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other drug-induced thrombocytopenias</strong> – Other drug-induced thrombocytopenias include drug-induced immune thrombocytopenia (DITP), drug-induced thrombotic thrombocytopenic purpura (DI-TTP) and drug-induced bone marrow suppression. Like DITMA, a temporal relationship with a drug may be elicited. Unlike DITMA, other forms of drug-induced thrombocytopenia (with the exception of DI-TTP) are not associated with microangiopathic hemolysis or organ damage from microvascular thrombosis. (See  <a class="medical medical_review" href="/d/html/6674.html" rel="external">"Drug-induced immune thrombocytopenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other drug-induced anemias</strong> – Other drug-induced anemias include immune-mediated hemolysis and glucose-6-phosphate dehydrogenase (G6PD) deficiency. Like DITMA, other drug-induced causes of hemolytic anemia are associated with a temporal relationship to drug exposure, and the Coombs test may be negative. Unlike DITMA, other drug-induced anemias typically do not cause fragmentation hemolysis, thrombocytopenia, kidney injury, or other end-organ manifestations. (See  <a class="medical medical_review" href="/d/html/7104.html" rel="external">"Drug-induced hemolytic anemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other drug-induced kidney injury</strong> – Many drugs are potentially nephrotoxic, and the possibility of direct kidney injury rather than injury mediated by the vascular lesion of TMA must be considered. Like DITMA, drug-induced kidney injury is associated with a temporal relation to drug exposure, rising serum creatinine, and in some cases anuria. Unlike DITMA there is no microangiopathic/fragmentation hemolysis or thrombocytopenia. (See  <a class="medical medical_review" href="/d/html/7216.html" rel="external">"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults", section on 'Nephrotoxins'</a> and  <a class="medical medical_review" href="/d/html/7234.html" rel="external">"Clinical manifestations and diagnosis of acute interstitial nephritis", section on 'Drugs'</a>.)</p><p></p><p class="headingAnchor" id="H10429277"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H174389"><span class="h2">Initial interventions</span><span class="headingEndMark"> — </span>Management of DITMA involves drug discontinuation and supportive care. </p><p>When our confidence in the diagnosis of DITMA is high, we do not use therapeutic plasma exchange (TPE) or anticomplement therapy. However, TPE may be appropriate when there is uncertainty about the diagnosis of DITMA versus thrombotic thrombocytopenic purpura (TTP); anticomplement therapy may be appropriate in patients with rapidly progressing kidney failure and uncertainty about the diagnosis of DITMA versus complement-mediated TMA. (See <a class="local">'Complement inhibition'</a> below.)</p><p>Early involvement of the consulting specialist is advised because there is a need to balance the risks and benefits of using or not using these other therapies, both of which have their own associated risks.</p><p>Our avoidance of TPE when there is a high level of confidence in the diagnosis of DITMA is supported by a lack of high-quality evidence for a benefit of TPE in DITMA and is consistent with recommendations from the American Society for Apheresis (ASFA), which publishes an evidence-based categorization of the usefulness of TPE on review of available evidence and considers <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> to be category IV (TPE ineffective or harmful) [<a href="#rid82">82</a>]. </p><p>For patients in whom TPE or anticomplement therapy has already been initiated, we base our decisions regarding continuation or discontinuation on our confidence that DITMA is the most likely diagnosis, and on the patient's clinical course. These decisions can be re-evaluated when additional clinical information becomes available, including the response to therapy, identification of alternative causes of the patient's symptoms, and results of other diagnostic testing. However, improvement during TPE or anticomplement therapy may be coincidental and does not necessarily imply a treatment response. (See  <a class="medical medical_review" href="/d/html/1344.html" rel="external">"Immune TTP: Initial treatment", section on 'Continuation and completion of therapy'</a>.)</p><p>Immunosuppressive therapy is not a component of DITMA management, although it may be appropriate if the diagnosis is unclear (glucocorticoids for patients in whom the diagnosis of immune TTP is suspected).</p><p>Supportive care may be needed: </p><p class="bulletIndent1"><span class="glyph">●</span>It is appropriate to transfuse platelets for severe thrombocytopenia associated with clinically important bleeding. (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Actively bleeding patient'</a> and  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'TTP or HIT'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Indications for dialysis and avoidance of nephrotoxic drugs are similar as with other patients with renal failure. (See  <a class="medical medical_review" href="/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dose reductions of nephrotoxic chemotherapeutic agents may be required for patients with residual kidney disease and reduced glomerular filtration rate. (See  <a class="medical medical_review" href="/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy"</a> and  <a class="medical medical_review" href="/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents", section on 'Dosing considerations for nephrotoxicity'</a>.)</p><p></p><p class="headingAnchor" id="H1010643061"><span class="h2">Investigational therapies for DITMA that does not resolve with drug discontinuation</span></p><p class="headingAnchor" id="H4142597006"><span class="h3">Complement inhibition</span><span class="headingEndMark"> — </span>There have been reports of patients with non-immune DITMA attributed to <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a>, interferon, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and other drugs; and case reports have described patients with acute kidney injury (AKI) attributed to gemcitabine that improved after treatment targeting complement activation [<a href="#rid83">83,84</a>]. We believe it is reasonable to consider <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> in persistent non-immune DITMA that does not improve with supportive care and withdrawal of the offending agent, or in patients with acute, severe immune-mediated DITMA who are at risk for the development of chronic kidney disease [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H3602115436"><span class="h3">N-acetylcysteine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a> (NAC) is a sulfhydryl-containing compound with potential roles in oxygen scavenging, endothelial cell relaxation, glutathione recycling, and reducing protein multimerization mediated by disulfide bonds. </p><p>NAC is safe, inexpensive, and may be effective for some cases of DITMA. We would have a low threshold for trying NAC in a patient with DITMA that does not resolve with drug discontinuation alone. </p><p>Supporting evidence includes:</p><p class="bulletIndent1"><span class="glyph">●</span>NAC was shown to reduce the concentration of ultra-large von Willebrand factor (VWF) multimers in vitro and in an animal model of TTP, suggesting that it may be an effective treatment in individuals with immune TTP by a similar mechanism (ie, it might reduce accumulation of ultra-large VWF multimers in the microvasculature) [<a href="#rid86">86,87</a>]. (See  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)", section on 'TTP pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NAC was administered to a patient with ponatinib-associated DITMA affecting the coronary microvasculature [<a href="#rid47">47</a>]. The patient had dramatic resolution of abnormal electrocardiogram (ECG) findings following treatment with NAC (150 mg/kg loading dose followed by two doses of 50 mg/kg given 12 hours apart). </p><p></p><p class="headingAnchor" id="H174395"><span class="h2">Future drug avoidance</span><span class="headingEndMark"> — </span>The importance of future drug avoidance depends on whether the DITMA is immune-mediated or non-immune.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune-mediated</strong> – The implicated agent must be completely avoided for life. Subsequent exposures can result in severe symptoms that may be fatal, even with lower doses or levels of exposure. Strict avoidance of the implicated drug should be noted clearly in the medical record. Patients who have recovered from quinine-induced TMA must be warned that even the low concentrations of <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> in beverages such as tonic water can cause a recurrent, severe episode. (See <a class="local">'Drugs (immune mechanism)'</a> above.)</p><p></p><p class="bulletIndent1">A patient should <strong>never</strong> be re-exposed to a drug potentially implicated in immune-mediated DITMA solely for the purpose of establishing the role of the drug, as this could be life threatening.</p><p></p><p class="bulletIndent1">A patient with immune-mediated DITMA may be able to receive an alternative agent within the same drug class, since drug-dependent antibodies may be specific for the individual drug. Antibodies against <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> may not react with <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a>, which is structurally similar. (See <a class="local">'Immune-mediated mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-immune </strong>– For non-immune DITMA that appears to be dose related, re-exposure to the implicated drug may be possible in selected cases. The decision must balance the potential risks of recurrent DITMA, which may be negligible with lower doses of the medication, versus the potential benefits of drug administration. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney injury with features of TMA may be seen with high doses of a calcineurin inhibitor but may not recur with lower doses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It may be appropriate to avoid an implicated chemotherapy agent in the palliative setting when other alternatives are available. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It may be possible to re-administer <a class="drug drug_general" data-topicid="115772" href="/d/drug information/115772.html" rel="external">emicizumab</a> if appropriate, as long as it is not coadministered with an <a class="drug drug_general" data-topicid="8434" href="/d/drug information/8434.html" rel="external">activated prothrombin complex concentrate</a> (aPCC).</p><p></p><p class="bulletIndent1">Alternative options for immunosuppression following hematopoietic stem cell and solid organ transplantation are presented separately. (See  <a class="medical medical_review" href="/d/html/7350.html" rel="external">"Thrombotic microangiopathy after kidney transplantation"</a> and  <a class="medical medical_review" href="/d/html/7331.html" rel="external">"Kidney function and non-kidney solid organ transplantation"</a> and  <a class="medical medical_review" href="/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a> and  <a class="medical medical_review" href="/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Thrombotic microangiopathy'</a>.)</p><p></p><p class="headingAnchor" id="H503583"><span class="h1">PROGNOSIS/EXPECTED RECOVERY</span><span class="headingEndMark"> — </span>Thrombocytopenia should begin to recover within several days.</p><p>Recovery of kidney function may be very slow and incomplete. Chronic kidney disease (creatinine clearance &lt;60 mL/min) was common in patients with quinine-induced TMA [<a href="#rid88">88</a>]. </p><p class="headingAnchor" id="H2812660760"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117846.html" rel="external">"Society guideline links: Thrombotic microangiopathies (TTP, HUS, and related disorders)"</a>.)</p><p class="headingAnchor" id="H11462653"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – We divide drug-induced thrombotic microangiopathy (DITMA) into immune-mediated syndromes and non-immune syndromes. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism</strong> – Immune-mediated DITMA can occur after exposure to small amounts of a substance via an antibody-dependent mechanism  (<a class="graphic graphic_figure graphicRef130247" href="/d/graphic/130247.html" rel="external">figure 1</a>). Non-immune DITMA has multiple mechanisms and is often dose dependent. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Implicated drugs</strong> – Drugs most commonly associated with DITMA are listed in the table  (<a class="graphic graphic_table graphicRef101685" href="/d/graphic/101685.html" rel="external">table 1</a>). (See <a class="local">'Drugs associated with DITMA'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immune</strong> – Causes include antimicrobials, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, and immunomodulatory agents. (See <a class="local">'Drugs (immune mechanism)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Non-immune</strong> – Common causes include type 1 interferon, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, some cancer therapies (<a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="8852" href="/d/drug information/8852.html" rel="external">dasatinib</a>, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, <a class="drug drug_general" data-topicid="87456" href="/d/drug information/87456.html" rel="external">ponatinib</a>, proteasome inhibitors, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>), calcineurin inhibitors (<a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>), and drugs of abuse (cocaine, intravenous use of <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> or extended-release <a class="drug drug_general" data-topicid="9733" href="/d/drug information/9733.html" rel="external">oxymorphone</a>). (See <a class="local">'Drugs (non-immune mechanism)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immune</strong> – Sudden onset of chills, fever, abdominal pain, diarrhea, nausea/vomiting, and/or hypotension, within hours after exposure to a drug (taken occasionally over years or new drug over two to three weeks). (See <a class="local">'Clinical features of immune DITMA'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Non-immune</strong> – Gradual weakness, fatigue, headache, and/or kidney failure over weeks to months. DITMA from drugs of abuse may cause sudden-onset systemic symptoms and acute kidney injury (AKI). (See <a class="local">'Clinical features of non-immune DITMA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – Testing includes complete blood count (CBC), blood smear review, hemolysis testing, kidney function, and coagulation testing. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis is made clinically with the appropriate exposure history and findings of thrombotic microangiopathy (TMA) including schistocytes on the blood smear, thrombocytopenia, and typically kidney injury. ADAMTS13 activity is &gt;10 percent. Drug-dependent antibodies may be identified in immune-mediated DITMA. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential</strong> – The differential diagnosis includes other primary TMAs such as thrombotic thrombocytopenic purpura (TTP) and other causes of AKI. Drug-induced TMA with ADAMTS13 activity ≤10 percent is considered drug-induced TTP (DI-TTP). (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation", section on 'Thrombotic microangiopathy'</a> and  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a> and  <a class="medical medical_review" href="/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Thrombotic microangiopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Management involves drug discontinuation and supportive care. Therapeutic plasma exchange (TPE) may be appropriate when there is uncertainty about possible TTP. Anticomplement therapy may be appropriate in patients with rapidly progressing kidney failure and possible complement-mediated TMA. Early involvement of the consulting specialist is advised. (See <a class="local">'Initial interventions'</a> above and <a class="local">'Investigational therapies for DITMA that does not resolve with drug discontinuation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – For immune-mediated DITMA, the implicated drug must be avoided for life. For non-immune DITMA, re-exposure may be possible in selected cases. (See <a class="local">'Future drug avoidance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recovery</strong> – Recovery may be incomplete because kidney damage may be severe. Thrombocytopenia begins to resolve within days. (See <a class="local">'Prognosis/expected recovery'</a> above.)</p><p></p><p class="headingAnchor" id="H1059676245"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lawrence LK Leung, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Al-Nouri ZL, Reese JA, Terrell DR, et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015; 125:616.</a></li><li><a class="nounderline abstract_t">Reese JA, Bougie DW, Curtis BR, et al. Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin. Am J Hematol 2015; 90:406.</a></li><li><a class="nounderline abstract_t">Khan S, George JN, Nusrat S. Drug-induced thrombotic microangiopathy and thrombotic thrombocytopenic purpura: A systematic review, 2018-2023. Am J Hematol 2023; 98:E373.</a></li><li><a class="nounderline abstract_t">Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357:580.</a></li><li><a class="nounderline abstract_t">George JN, Morton JM, Liles NW, Nester CM. After the Party's Over. N Engl J Med 2017; 376:74.</a></li><li><a class="nounderline abstract_t">Saleem R, Reese JA, George JN. Drug-induced thrombotic microangiopathy: An updated systematic review, 2014-2018. Am J Hematol 2018; 93:E241.</a></li><li class="breakAll">George JN. Drug-Induced Thrombotic Microangiopathy (DITMA). Available at: https://www.ouhsc.edu/platelets/DITMA.htm (Accessed on March 12, 2023).</li><li><a class="nounderline abstract_t">Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342:1773.</a></li><li><a class="nounderline abstract_t">Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998; 128:541.</a></li><li><a class="nounderline abstract_t">Page EE, Little DJ, Vesely SK, George JN. Quinine-Induced Thrombotic Microangiopathy: A Report of 19 Patients. Am J Kidney Dis 2017; 70:686.</a></li><li class="breakAll">RIFADIN® (rifampin capsules USP) and RIFADIN® IV (rifampin for injection USP). US Food and Drug Administration (FDA) approved product information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050420s088,050627s033lbl.pdf (Accessed on March 23, 2023).</li><li><a class="nounderline abstract_t">Fahal IH, Williams PS, Clark RE, Bell GM. Thrombotic thrombocytopenic purpura due to rifampicin. BMJ 1992; 304:882.</a></li><li><a class="nounderline abstract_t">Gupta R, Wargo KA. Rifampin-induced thrombotic thrombocytopenic purpura. Ann Pharmacother 2005; 39:1761.</a></li><li><a class="nounderline abstract_t">Saif MW, Xyla V, Makrilia N, et al. Thrombotic microangiopathy associated with gemcitabine: rare but real. Expert Opin Drug Saf 2009; 8:257.</a></li><li><a class="nounderline abstract_t">Crouzet L, Edeline J, Le Du F, et al. Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma. Acta Oncol 2012; 51:687.</a></li><li><a class="nounderline abstract_t">Huynh M, Chee K, Lau DH. Thrombotic thrombocytopenic purpura associated with quetiapine. Ann Pharmacother 2005; 39:1346.</a></li><li><a class="nounderline abstract_t">Dussol B, Brunet P, Vacher-Coponat H, et al. Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy. Nephrol Dial Transplant 1994; 9:1191.</a></li><li><a class="nounderline abstract_t">Zbaras B, Sam LN, Grimm MC. Thrombotic thrombocytopenic purpura associated with adalimumab (Humira) treatment in Crohn disease. Intern Med J 2013; 43:216.</a></li><li><a class="nounderline abstract_t">Falsetti L, Sampaolesi M, Riccomi F, Nitti C. Adalimumab as a potential cause of drug-induced thrombocytopaenic microangiopathy. BMJ Case Rep 2020; 13.</a></li><li><a class="nounderline abstract_t">Klomjit N, Evans R, Le TK, et al. Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance database. Am J Hematol 2023; 98:E369.</a></li><li><a class="nounderline abstract_t">Leal F, Macedo LT, Carvalheira JB. Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series. J Chemother 2014; 26:169.</a></li><li><a class="nounderline abstract_t">Price TM, Murgo AJ, Keveney JJ, et al. Renal failure and hemolytic anemia associated with mitomycin C. A case report. Cancer 1985; 55:51.</a></li><li><a class="nounderline abstract_t">Poch E, González-Clemente JM, Torras A, et al. Silent renal microangiography after mitomycin C therapy. Am J Nephrol 1990; 10:514.</a></li><li><a class="nounderline abstract_t">Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 1985; 3:723.</a></li><li><a class="nounderline abstract_t">Groff JA, Kozak M, Boehmer JP, et al. Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis 1997; 29:280.</a></li><li><a class="nounderline abstract_t">Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7:781.</a></li><li><a class="nounderline abstract_t">El-Ghazal R, Podoltsev N, Marks P, et al. Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer 2011; 10:142.</a></li><li><a class="nounderline abstract_t">Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 1985; 55:47.</a></li><li><a class="nounderline abstract_t">Rabadi SJ, Khandekar JD, Miller HJ. Mitomycin-induced hemolytic uremic syndrome: case presentation and review of literature. Cancer Treat Rep 1982; 66:1244.</a></li><li><a class="nounderline abstract_t">Grem JL, Merritt JA, Carbone PP. Treatment of mitomycin-associated microangiopathic hemolytic anemia with vincristine. Arch Intern Med 1986; 146:566.</a></li><li><a class="nounderline abstract_t">Harris DC, Lawrence S, Bradstock KF, et al. Intraglomerular thrombosis with deoxycoformycin--reversible acute renal failure. Clin Nephrol 1984; 21:194.</a></li><li><a class="nounderline abstract_t">Leach JW, Pham T, Diamandidis D, George JN. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): A case report. Am J Hematol 1999; 61:268.</a></li><li><a class="nounderline abstract_t">Kanchi H, Webb NJ, Eden OB. Hemolytic uremic syndrome secondary to the treatment of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2000; 22:483.</a></li><li><a class="nounderline abstract_t">Yui JC, Van Keer J, Weiss BM, et al. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol 2016; 91:E348.</a></li><li><a class="nounderline abstract_t">Yui JC, Dispenzieri A, Leung N. Ixazomib-induced thrombotic microangiopathy. Am J Hematol 2017; 92:E53.</a></li><li><a class="nounderline abstract_t">Philipponnet C, Aniort J, Atenza A, et al. Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid. Kidney Int Rep 2022; 7:2746.</a></li><li><a class="nounderline abstract_t">Myall NJ, Wang SX, Hall ET, et al. Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma. Fed Pract 2022; 39:S56.</a></li><li><a class="nounderline abstract_t">Eigbire-Molen O, Hermelin D, Blackall D. Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis. J Med Cases 2022; 13:274.</a></li><li><a class="nounderline abstract_t">Terao T, Tsushima T, Miura D, et al. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review. Leuk Lymphoma 2022; 63:1102.</a></li><li><a class="nounderline abstract_t">Scheggi V, Merilli I, Cesaroni E, Alterini B. Carfilzomib-induced thrombotic microangiopathy. A case report. J Oncol Pharm Pract 2022; 28:754.</a></li><li><a class="nounderline abstract_t">Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129.</a></li><li><a class="nounderline abstract_t">Frangié C, Lefaucheur C, Medioni J, et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8:177.</a></li><li><a class="nounderline abstract_t">Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007; 18:1745.</a></li><li><a class="nounderline abstract_t">Hofmann Jan C, Kiprov Dobri D. Sunitinib associated thrombotic microangiopathy in a patient with renal cell carcinoma: A new cause of TTP-HUS? J Clin Apher 2008; 23:42.</a></li><li><a class="nounderline abstract_t">Launay-Vacher V, Aapro M, De Castro G Jr, et al. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 2015; 26:1677.</a></li><li><a class="nounderline abstract_t">Latifi Y, Moccetti F, Wu M, et al. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood 2019; 133:1597.</a></li><li><a class="nounderline abstract_t">Wu MD, Hodovan J, Kumar K, et al. Ponatinib coronary microangiopathy: novel bedside diagnostic approach and management with N-acetylcysteine. Blood Adv 2020; 4:4083.</a></li><li><a class="nounderline abstract_t">Chapin J, Shore T, Forsberg P, et al. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol 2014; 12:565.</a></li><li><a class="nounderline abstract_t">Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011; 118:1452.</a></li><li><a class="nounderline abstract_t">Remuzzi G, Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989; 13:261.</a></li><li class="breakAll">Laszik ZG, Kambham N, Silva FG. Thrombotic microangiopathies. In: Heptinstall's Pathology of the Kidney, Jennett JC, D'Agati VD, Olson JL, Silva FG (Eds), Lippincott-Raven, Philadelphia 2014.</li><li><a class="nounderline abstract_t">Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5:2441.</a></li><li><a class="nounderline abstract_t">Kavanagh D, McGlasson S, Jury A, et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood 2016; 128:2824.</a></li><li><a class="nounderline abstract_t">George JN. Interferon-induced thrombotic microangiopathy. Blood 2016; 128:2753.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:1.</a></li><li><a class="nounderline abstract_t">Amjad AI, Parikh RA. Opana-ER used the wrong way: intravenous abuse leading to microangiopathic hemolysis and a TTP-like syndrome. Blood 2013; 122:3403.</a></li><li><a class="nounderline abstract_t">Volcy J, Nzerue CM, Oderinde A, Hewan-Iowe K. Cocaine-induced acute renal failure, hemolysis, and thrombocytopenia mimicking thrombotic thrombocytopenic purpura. Am J Kidney Dis 2000; 35:E3.</a></li><li><a class="nounderline abstract_t">Hunt R, Yalamanoglu A, Tumlin J, et al. A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. Blood 2017; 129:896.</a></li><li><a class="nounderline abstract_t">Robson KJ, Clucas D, Filshie R, Nandurkar H. Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Tate C, Mollee P. Intravenous OxyContin-associated thrombotic microangiopathy treated successfully without plasma exchange. Med J Aust 2015; 202:330.</a></li><li><a class="nounderline abstract_t">Nataatmadja M, Divi D. Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone. Clin Kidney J 2016; 9:580.</a></li><li><a class="nounderline abstract_t">Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017; 377:809.</a></li><li class="breakAll">Highlights of prescribing information: Zolgensma. Food and Drug Administration. Available at: https://www.fda.gov/media/126109/download (Accessed on July 28, 2022).</li><li><a class="nounderline abstract_t">Guillou J, de Pellegars A, Porcheret F, et al. Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv 2022; 6:4266.</a></li><li><a class="nounderline abstract_t">Chand DH, Zaidman C, Arya K, et al. Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series. J Pediatr 2021; 231:265.</a></li><li class="breakAll">Rocket pharmaceuticals announces positive updates from Phase 1 clinical trial of RP-A501 in Danon Disease. Rocket Pharmaceuticals. Available at: https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-positive-updates-phase-1/ (Accessed on July 28, 2022).</li><li><a class="nounderline abstract_t">Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Ther 2021; 29:464.</a></li><li><a class="nounderline abstract_t">George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371:654.</a></li><li><a class="nounderline abstract_t">Liles NW, Page EE, Liles AL, et al. Diversity and severity of adverse reactions to quinine: A systematic review. Am J Hematol 2016; 91:461.</a></li><li><a class="nounderline abstract_t">Spearing RL, Hickton CM, Sizeland P, et al. Quinine-induced disseminated intravascular coagulation. Lancet 1990; 336:1535.</a></li><li><a class="nounderline abstract_t">Schmitt SK, Tomford JW. Quinine-induced pancytopenia and coagulopathy. Ann Intern Med 1994; 120:90.</a></li><li><a class="nounderline abstract_t">Morton AP. Quinine-induced disseminated intravascular coagulation and haemolytic-uraemic syndrome. Med J Aust 2002; 176:351.</a></li><li><a class="nounderline abstract_t">Baliga RS, Wingo CS. Quinine induced HUS-TTP: an unusual presentation. Am J Med Sci 2003; 326:378.</a></li><li><a class="nounderline abstract_t">Lim AK, Ho L, Levidiotis V. Quinine-induced renal failure as a result of rhabdomyolysis, haemolytic uraemic syndrome and disseminated intravascular coagulation. Intern Med J 2006; 36:465.</a></li><li><a class="nounderline abstract_t">Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41.</a></li><li><a class="nounderline abstract_t">Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004; 100:2664.</a></li><li><a class="nounderline abstract_t">Raife TJ, Lager DJ. Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects. Mayo Clin Proc 2002; 77:323.</a></li><li><a class="nounderline abstract_t">Ruutu T, Hermans J, Niederwieser D, et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118:1112.</a></li><li><a class="nounderline abstract_t">Miller PJ, Farland AM, Knovich MA, et al. Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange. Am J Hematol 2014; 89:695.</a></li><li class="breakAll">https://www.bcw.edu/bcw/Diagnostics/Testing-Services/index.htm (Accessed on May 19, 2015).</li><li class="breakAll">https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home (Accessed on May 26, 2015).</li><li><a class="nounderline abstract_t">Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher 2016; 31:149.</a></li><li><a class="nounderline abstract_t">Riedl M, Fakhouri F, Le Quintrec M, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 2014; 40:444.</a></li><li><a class="nounderline abstract_t">Turner JL, Reardon J, Bekaii-Saab T, et al. Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. Clin Colorectal Cancer 2016.</a></li><li><a class="nounderline abstract_t">Grall M, Daviet F, Chiche NJ, et al. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC Nephrol 2021; 22:267.</a></li><li><a class="nounderline abstract_t">Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011; 121:593.</a></li><li><a class="nounderline abstract_t">George JN, López JA, Konkle BA. N-Acetylcysteine: an old drug, a new insight, a potentially effective treatment for thrombotic thrombocytopenic purpura. Transfusion 2014; 54:1205.</a></li><li><a class="nounderline abstract_t">Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med 2001; 135:1047.</a></li></ol></div><div id="topicVersionRevision">Topic 98720 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25414441" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug-induced thrombotic microangiopathy: a systematic review of published reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25639727" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37753669" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Drug-induced thrombotic microangiopathy and thrombotic thrombocytopenic purpura: A systematic review, 2018-2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17687133" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Drug-induced immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28052232" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : After the Party's Over.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985540" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Drug-induced thrombotic microangiopathy: An updated systematic review, 2014-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985540" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Drug-induced thrombotic microangiopathy: An updated systematic review, 2014-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852999" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Thrombotic thrombocytopenic purpura associated with clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9518398" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780041" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Quinine-Induced Thrombotic Microangiopathy: A Report of 19 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780041" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Quinine-Induced Thrombotic Microangiopathy: A Report of 19 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1392753" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Thrombotic thrombocytopenic purpura due to rifampicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16144880" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rifampin-induced thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19505260" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thrombotic microangiopathy associated with gemcitabine: rare but real.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22356625" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914516" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thrombotic thrombocytopenic purpura associated with quetiapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7800227" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23402489" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Thrombotic thrombocytopenic purpura associated with adalimumab (Humira) treatment in Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139450" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Adalimumab as a potential cause of drug-induced thrombocytopaenic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37740927" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24091354" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3917354" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Renal failure and hemolytic anemia associated with mitomycin C. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2127509" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Silent renal microangiography after mitomycin C therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3923162" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9016902" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2497229" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21859568" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3917353" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Renal complications of mitomycin C therapy with special reference to the total dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7083229" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mitomycin-induced hemolytic uremic syndrome: case presentation and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3954531" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of mitomycin-associated microangiopathic hemolytic anemia with vincristine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6608428" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intraglomerular thrombosis with deoxycoformycin--reversible acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440915" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11037870" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hemolytic uremic syndrome secondary to the treatment of acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27286661" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Proteasome inhibitor associated thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28133842" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ixazomib-induced thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36506224" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36426106" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35837078" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35373680" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34904466" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Carfilzomib-induced thrombotic microangiopathy. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337603" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : VEGF inhibition and renal thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267332" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17890216" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Sunitinib associated thrombotic microangiopathy in a patient with renal cell carcinoma: A new cause of TTP-HUS?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25735315" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30692122" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32870969" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ponatinib coronary microangiopathy: novel bedside diagnostic approach and management with N-acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25654478" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21596850" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2650537" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Renal vascular and thrombotic effects of cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2650537" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Renal vascular and thrombotic effects of cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162193" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27663672" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27979867" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Interferon-induced thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23302815" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24369032" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Opana-ER used the wrong way: intravenous abuse leading to microangiopathic hemolysis and a TTP-like syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620564" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cocaine-induced acute renal failure, hemolysis, and thrombocytopenia mimicking thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864296" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28716778" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832162" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Intravenous OxyContin-associated thrombotic microangiopathy treated successfully without plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27478601" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28691557" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Emicizumab Prophylaxis in Hemophilia A with Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28691557" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Emicizumab Prophylaxis in Hemophilia A with Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35584395" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33259859" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33259859" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33309881" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Current Clinical Applications of In Vivo Gene Therapy with AAVs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25119611" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Syndromes of thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26822544" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diversity and severity of adverse reactions to quinine: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1979368" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Quinine-induced disseminated intravascular coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8250466" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Quinine-induced pancytopenia and coagulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12013332" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Quinine-induced disseminated intravascular coagulation and haemolytic-uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671503" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Quinine induced HUS-TTP: an unusual presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16780456" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Quinine-induced renal failure as a result of rhabdomyolysis, haemolytic uraemic syndrome and disseminated intravascular coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6203452" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15197810" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Gemcitabine-associated thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11936926" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12199793" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24668845" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24668845" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24668845" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27322218" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24911558" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27743743" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34284729" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21266777" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24819072" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : N-Acetylcysteine: an old drug, a new insight, a potentially effective treatment for thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11747383" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
